XML 77 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Operations (USD $)
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Revenue:      
Revenue from licensing agreements, grants and other $ 511,558 $ 557,880 $ 927,772
Revenue from product sales 856,397 662,790 499,200
Total revenue 1,367,955 1,220,670 1,426,972
Cost of product sales 263,188 214,811 168,424
Gross profit 1,104,767 1,005,859 1,258,548
Operating expenses:      
Research and development 15,846,829 19,937,764 21,019,301
Selling, general and administrative 7,447,235 8,202,375 9,376,774
Wind-down expenses 356,379 287,122 221,991
Impairment of intangible asset   654,961  
Total operating expenses 23,650,443 29,082,222 30,618,066
Operating loss (22,545,676) (28,076,363) (29,359,518)
Other income (expense):      
Realized gain on sale of marketable securities   83,750  
Change in fair value of warrant liability (5,944,571) 6,612,092 3,005,040
Interest income 15,594 13,942 26,728
Interest expense (50,193) (71,363) (93,382)
Qualifying therapeutic discovery project grant     977,917
Other income (expense), net 33,693 109,404 199,664
Total other income (expense), net (5,945,477) 6,747,825 4,115,967
Net loss $ (28,491,153) $ (21,328,536) $ (25,243,551)
Basic and diluted net loss per share $ (0.99) $ (1.50) $ (2.05)
Shares used to compute basic and diluted loss per share 28,824,417 14,187,885 12,330,299